English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduEMBARGOED UNTIL 8:30AM, May 16, 2022
Several retrospective studies have evaluated whether concurrent surgical correction of the tricuspid valve at the time of LVAD implantation can reduce post-operative RHF and improve outcomes. Most of these studies did not demonstrate a significant benefit for concomitant tricuspid surgery; however, these analyses are inherently limited by selection bias.
“We felt that this question had not been definitively answered, so we decided to perform a randomized controlled study on this topic,” said presenter Yuting Chiang, MD, New York Presbyterian/Columbia University Medical Center.
The purpose of the TVVAD trial was to determine the utility of tricuspid valve repair at the time of LVAD implantation for patients who present moderate or severe tricuspid regurgitation (TR). This study evaluated whether concurrent surgical correction of moderate or greater TR in patients undergoing LVAD implantation prevents post-operative right heart failure (RHF) compared to LVAD implantation alone. Dr. Chiang explained, “We used an adaptive trial design with a planned interim analysis to allow for early stopping of the trial for efficacy or futility and to allow for sample size re-estimation.”
Sixty patients with moderate or severe TR on pre-operative echocardiography were randomized to either LVAD implantation alone (No TVR, n=28) or LVAD implantation with concomitant tricuspid valve surgery (TVR, n=32). Randomization was stratified by pre-operative right ventricular (RV) dysfunction (none/mild vs moderate vs severe).
There was no significant difference in the primary outcome of the two arms. At six months, 46.43% of the TVR group and 43.75% of the No TVR group had experienced moderate to severe RHF. The study also looked at the incidence of all-cause mortality, atrioventricular block, major bleeding, prolonged mechanical ventilation, unplanned RVAD, and stroke and found no statistically significant difference. Based on this analysis, the trial has been discontinued for futility. Dr. Chiang said that they plan to follow-up with these patients and perform another analysis at one year to evaluate whether there are long-term benefits.
Muath Bishawi, MD, cardiothoracic surgery resident, Duke University, Durham, NC, and co-principal investigator for the trial, added “In our study, we focused on the primary endpoint, which was right heart dysfunction up to six months. Many other endpoints in the study, however, may be of interest to focus on for future trials. These may include late re-admissions beyond six months, quality-adjusted life years, and cost in hospital and long-term care.”
###
Presented by Yuting Chiang, MD, May 16, 2022, at the AATS 102nd Annual Meeting
ABOUT THE AMERICAN ASSOCIATION FOR THORACIC SURGERY (AATS)
The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premiere association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit www.aats.org to learn more.
